209 related articles for article (PubMed ID: 37063928)
21. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
Yang YL; Wang J; Zhao LZ; Gao ZF; Jing HM; Ke XY
Ai Zheng; 2008 Jun; 27(6):636-41. PubMed ID: 18570740
[TBL] [Abstract][Full Text] [Related]
22. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
[No Abstract] [Full Text] [Related]
23. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
24. [Expression of CD30 in Patients with Diffuse Large B-Cell Lymphoma and Clinical Significance].
Qu Y; Lu XZ; Wang RX; Hei XF; Li J; Xiao BT; Jia ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):450-457. PubMed ID: 38660851
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].
Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019
[TBL] [Abstract][Full Text] [Related]
26. Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China.
Chen B; Cao DH; Lai L; Guo JB; Chen ZY; Huang Y; Qiu S; Lin TH; Gou Y; Ma N; Yang L; Liu LR; Wei Q
BMC Cancer; 2020 Mar; 20(1):220. PubMed ID: 32171265
[TBL] [Abstract][Full Text] [Related]
27. [A retrospective analysis of clinical characteristics and prognostic factors for 124 cases of primary gastric lymphomas].
He Y; Wang L; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):505-510. PubMed ID: 28655094
[No Abstract] [Full Text] [Related]
28. Central Nervous System Involvement in Patients with Diffuse Large B Cell Lymphoma: Analysis of the Risk Factors and Prognosis from a Single-Center Retrospective Cohort Study.
Ma J; Li Q; Shao J; Ma Y; Lin Z; Kang H; Chen B
Cancer Manag Res; 2019; 11():10175-10185. PubMed ID: 31819650
[TBL] [Abstract][Full Text] [Related]
29. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
30. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
[TBL] [Abstract][Full Text] [Related]
31. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
32. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Leonard JP; Kolibaba KS; Reeves JA; Tulpule A; Flinn IW; Kolevska T; Robles R; Flowers CR; Collins R; DiBella NJ; Papish SW; Venugopal P; Horodner A; Tabatabai A; Hajdenberg J; Park J; Neuwirth R; Mulligan G; Suryanarayan K; Esseltine DL; de Vos S
J Clin Oncol; 2017 Nov; 35(31):3538-3546. PubMed ID: 28862883
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
[TBL] [Abstract][Full Text] [Related]
34. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
35. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
36. Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors.
Huang J; Jiang W; Xu R; Huang H; Lv Y; Xia Z; Sun X; Guan Z; Lin T; Li Z
BMC Cancer; 2010 Jul; 10():358. PubMed ID: 20604963
[TBL] [Abstract][Full Text] [Related]
37. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.
Wang Y; Link BK; Witzig TE; Maurer MJ; Allmer C; King RL; Feldman AL; Habermann TM; Ansell SM; Slager SL; Cerhan JR; Nowakowski GS
Blood; 2019 Oct; 134(16):1289-1297. PubMed ID: 31350266
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
39. CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.
Li YJ; Li ZM; Rao HL; Xia Y; Huang HQ; Xia ZJ; Li S; Li WY; Jiang WQ
J Transl Med; 2012 May; 10():84. PubMed ID: 22554077
[TBL] [Abstract][Full Text] [Related]
40. A Novel Prognostic Score Including the CD4/CD8 for AIDS-Related Lymphoma.
Chen J; Liu X; Qin S; Ruan G; Lu A; Zhang J; Wu Y; Xie Z; Peng J
Front Cell Infect Microbiol; 2022; 12():919446. PubMed ID: 35873145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
